Skip to main content Skip to section navigation Skip to footer
Maravai LifeSciences
  • Contact
  • About
    • About Maravai
    • Leadership
    • Board of Directors
    • Innovation
    • Supply Chain
    • Operations
    • Our People
  • Brands
    • Our Brands
    • TriLink BioTechnologies
    • Cygnus Technologies
    • Glen Research
    • Alphazyme
  • Impact
    • Our Impact
    • Maravai Foundation
  • Insights
    • Our Insights
    • Latest news
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • SEC Filings
    • Sustainability
    • Governance
  • Careers
    • Be a #MiracleMaker
    • Current Openings
    • Benefits and Growth
    • Culture and People

Press releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
    • R&D Day 2023
  • Company Info
    • Company Profile
    • Leadership
    • Annual Reports & Proxy
    • Contacts
    • FAQ
    • Analyst Coverage
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Sustainability
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Whistleblower Policy
  • News & Events

  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
  • R&D Day 2023
Dec 1, 2022 4:01 PM EST

Maravai LifeSciences Announces Updated CEO Leadership Transition Plans

Nov 16, 2022 5:05 PM EST

Maravai LifeSciences Named to the 2022 Deloitte Technology Fast 500™ List of Fastest-Growing Companies in North America

Nov 7, 2022 4:10 PM EST

New Kit Predicts Retroviral Particle Clearance in Biopharmaceutical Manufacturing

Nov 3, 2022 4:05 PM EDT

Maravai LifeSciences Announces November and December 2022 Investor Conference Schedule

Nov 2, 2022 4:05 PM EDT

Maravai LifeSciences Reports Third Quarter 2022 Financial Results

Oct 19, 2022 8:10 AM EDT

Maravai LifeSciences Temporarily Reinstates Carl Hull as CEO Amidst Pending Noncompetition Litigation

Oct 18, 2022 4:15 PM EDT

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 2, 2022

Oct 3, 2022 4:05 PM EDT

Maravai LifeSciences Announces CEO Leadership Transition

Sep 13, 2022 8:00 AM EDT

TriLink BioTechnologies, Part of Maravai LifeSciences, Expands its mRNA Raw Material Offering with the First GMP-grade Modified Nucleoside-Triphosphate Product

Aug 15, 2022 4:05 PM EDT

Maravai LifeSciences Announces September 2022 Investor Conference Schedule

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
Maravai LifeSciences and its brands are the proven catalysts for helping deliver novel vaccines, therapeutics and diagnostics with biotech, biopharma and life sciences companies across the globe.

Extraordinary science.
Everyday miracles.

  • About
    • Leadership
    • Board of Directors
    • Innovation
    • Supply chain
    • Operations
    • Diversity, equity, and inclusion
  • Brands
    • TriLink BioTechnologies
    • Cygnus Technologies
    • Glen Research
    • Alphazyme
  • Helpful links
    • Investors
    • Insights
    • Be a #MiracleMaker
    • Current openings

Connect with us

  • LinkedIn
  • Terms
  • Privacy notice
  • Site map
© 2025 Maravai LifeSciences. All rights reserved